VerImmune accepted into the Nanotechnology Characterization Laboratory at Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute

Collaboration with the NCL at the Frederick National Laboratory for Cancer research seeks to potentially further strengthen VerImmune's existing manufacturing data and controls for future regulatory submissions

WASHINGTON, DC (PRWEB) AUGUST 11, 2022. VerImmune, Inc. (“VerImmune”), a biotechnology company developing new oncology therapeutic modalities that redirect the body’s pre-existing immunity toward cancer, announced today that it has been accepted into the fully sponsored Assay Cascade characterization and testing program conducted by the Nanotechnology Characterization Laboratory (NCL) at the National Cancer Institute’s, part of the National Institutes of Health, Frederick National Laboratory for Cancer Research.

Nanomedicines accepted into the NCL Assay Cascade program undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy, and pharmacokinetics. The studies are tailored to each individual nanomedicine and are designed to promote the clinical translation of these novel therapies. All studies are funded by the NCI and conducted free of charge for Awardees.

“We are excited to be accepted into this highly competitive program sponsored by the National Cancer Institute” said John Troyer, COO of VerImmune Inc and Principal Investigator. “Acceptance into this program is an important step in validating our strategy since NCL accepts proposals with strong clinical potential. We look forward to this collaboration which will strengthen our existing manufacturing data for FDA submissions.”

About VerImmune
VerImmune is a biotechnology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection (AIR). This strategy utilizes a proprietary virus-inspired particle (ViP) platform that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors. This unique mechanism of action allows differentiation within the competitive Immuno-Oncology market. Importantly, it potentially changes the treatment paradigm for many patients who have un-treatable cancers due to limited options or resistance.
For more information visit: http://www.verimmune.com